Neoadjuvant chemotherapy has come into widespread use in breast cancer based on a flawed rationale and it is now time to limit its use, UK oncologists say. In an article in The BMJ, a group of UK-based oncologists say the dramatic shrinkage of primary tumours seen with neoadjuvant chemotherapy does not translate into survival benefits ...
Is it time to curb overuse of neoadjuvant chemotherapy?
By Michael Woodhead
17 Jan 2018